1. Adamson R, Jones AS, Field JK. Loss of heterozygosity studies on chromosome 17 in head and neck cancer using microsatellite markers. Oncogene. 1994;9(7):2077–82.
2. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333 (6046):1154–7. doi: 10.1126/science.1206923.
3. Ahomadegbe JC, Barrois M, Fogel S, Le Bihan ML, Douc-Rasy S, Duvillard P, Armand JP, Riou G. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene. 1995;10(6):1217–27.
4. Akhoondi S, Sun D, der Lehr N von, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 2007;67(19):9006–12. doi: 10.1158/0008-5472.CAN-07-1320.
5. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A, Teague J, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 2004;91(2):355–8. doi: 10.1038/sj.bjc.6601894.